文献速递神经免疫

托珠单抗与硫唑嘌呤治疗高复发型视神经脊髓炎谱系疾病的TANGO试验

Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
PubMed 文献 · Lancet Neurol · 2020-01-01

TANGO为在中国6家医院开展的多中心、开放标签、随机2期试验,纳入118例高复发型NMOSD成人患者,1:1接受静脉托珠单抗或口服硫唑嘌呤。两组不良事件总体相近,治疗相关不良事件托珠单抗组较少。

要点

  • 托珠单抗较硫唑嘌呤显著延长高复发型NMOSD首次复发时间并降低复发风险
  • 治疗相关不良事件托珠单抗36/59(61%)低于硫唑嘌呤49/59(83%)

核心结论

  • 在高复发型NMOSD患者中,托珠单抗较硫唑嘌呤显著降低后续复发风险,可能成为安全有效的预防复发治疗选择。

研究设计与样本

  • 开放标签、多中心、随机、2期试验,在中国6家医院开展,2017年11月1日至2018年8月3日入组118例成人高复发型NMOSD患者,1:1随机分配至托珠单抗组59例或硫唑嘌呤组59例。
  • 托珠单抗为静脉8 mg/kg每4周,硫唑嘌呤为口服2-3 mg/kg每日,计划最短治疗60周;全分析集118例,符合方案集108例(托珠单抗56例、硫唑嘌呤52例)。

主要发现

  • 不良事件托珠单抗组57/59(97%)、硫唑嘌呤组56/59(95%);治疗相关不良事件分别为36/59(61%)与49/59(83%);两组各1例(2%)死亡,均与治疗无关。

关键数值与推荐

  • 主要结局为全分析集与符合方案集中首次复发时间,全分析集为主要分析人群。

临床怎么用

  • 对高复发型NMOSD成人患者,可考虑托珠单抗作为减少复发的治疗选择,尤其合并自身免疫病者可能获益更明显。
  • 用药期间需监测不良事件;本研究为开放标签设计,治疗分配对研究者和患者未设盲,解读疗效时需结合这一背景。

局限性

  • 开放标签设计,研究者和患者知晓治疗分配,仅中央评审委员会、EDSS评分者、实验室人员和放射科医师设盲。
  • 为2期试验、样本量118例、随访至研究结束,长期安全性与疗效尚未明确。
  • 单中心区域为中国的6家医院,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Azathioprine is used as a first-line treatment to prevent relapses of neuromyelitis optica spectrum disorder (NMOSD). Tocilizumab has been reported to reduce NMOSD disease activity in retrospective case reports. We aimed to compare the safety and efficacy of tocilizumab and azathioprine in patients with highly relapsing NMOSD. METHODS: We did an open-label, multicentre, randomised, phase 2 trial at six hospitals in China. We recruited adult patients (aged ≥18 years) with highly relapsing NMOSD diagnosed according to 2015 International Panel for Neuromyelitis Optica Diagnosis criteria, who had an Expanded Disability Status Scale (EDSS) score of 7·5 or lower, and had a history of at least two clinical relapses during the previous 12 months or three relapses during the previous 24 months with at least one relapse within the previous 12 months. Patients were randomly assigned (1:1) to intravenous tocilizumab (8 mg/kg every 4 weeks) or oral azathioprine (2-3 mg/kg per day) by an independent statistician using computer-generated randomisation software with permuted blocks of four. The central review committee, EDSS raters, laboratory personnel, and radiologists were masked to the treatment assignment, but investigators and patients were aware of treatment allocation. The minimum planned duration of treatment was 60 weeks following randomisation. The primary outcome was time to first relapse in the full analysis set, which included all randomly assigned patients who received at least one dose of study drug, and the per-protocol population, which included all patients who used azathioprine or tocilizumab as monotherapy. For the analyses of the primary outcome, the patients were prespecified into two subgroups according to concomitant autoimmune disease status. Safety was assessed in the full analysis set. This study is registered with ClinicalTrials.gov, NCT03350633. FINDINGS: Between Nov 1, 2017, and Aug 3, 2018, we enrolled 118 patients, of whom 59 were randomly assigned to tocilizumab and 59 were randomly assigned to azathioprine. All 118 patients received one dose of study drug and were included in the full analysis set. 108 participants were included in the per-protocol analysis (56 in the tocilizumab group and 52 in the azathioprine group). In the full analysis set, median time to the first relapse was longer in the tocilizumab group than the azathioprine group (78·9 weeks [IQR 58·3-90·6] vs 56·7 [32·9-81·7] weeks; p=0·0026). Eight (14%) of 59 patients in the tocilizumab group and 28 (47%) of 59 patients in the azathioprine group had a relapse at the end of the study (hazard ratio [HR] 0·236 [95% CI 0·107-0·518]; p<0·0001). In the per-protocol analysis, 50 (89%) of 56 patients in the tocilizumab group were relapse-free compared with 29 (56%) of 52 patients in the azathioprine group at the end of the study (HR 0·188 [95% CI 0·076-0·463]; p<0·0001); the median time to first relapse was also longer in the tocilizumab group than the azathioprine group (67·2 weeks [IQR 47·9-77·9] vs 38·0 [23·6-64·9]; p<0·0001). In the prespecified subgroup analysis of the full analysis set stratified by concomitant autoimmune diseases, among patients without concomitant autoimmune diseases, three (9%) of 34 patients in the tocilizumab group and 13 (35%) of 37 patients in the azathioprine group had relapsed by the end of the study. Among patients with concomitant autoimmune diseases, a lower proportion of patients in the tocilizumab group had a relapse than in the azathioprine group (five [20%] of 25 patients vs 15 [68%] of 22 patients; HR 0·192 [95% CI 0·070-0·531]; p=0·0004). 57 (97%) of 59 patients in the tocilizumab group and 56 (95%) of 59 patients in the azathioprine group had adverse events. Treatment-associated adverse events occurred in 36 (61%) of 59 tocilizumab-treated patients and 49 (83%) of 59 azathioprine-treated patients. One death (2%) occurred in the tocilizumab group and one (2%) in the azathioprine group, but neither of the deaths were treatment-related. INTERPRETATION: Tocilizumab significantly reduced the risk of a subsequent NMOSD relapse compared with azathioprine. Tocilizumab might therefore be another safe and effective treatment to prevent relapses in patients with NMOSD. FUNDING: Tianjin Medical University, Advanced Innovation Center for Human Brain Protection, National Key Research and Development Program of China, National Science Foundation of China.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Zhang C, Zhang M, Qiu W, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020. PMID: 32333897. doi:10.1016/S1474-4422(20)30070-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。